Introduction: Current treatment of Parkinson’s disease (PD) is limited to symptomatic dopaminergic therapy, while no interventions have been shown to slow down disease progression.
Areas covered: The following article highlights a group of PPAR-γ agonists called thiazolidinediones (TZDs), which are currently being tested for a putative disease-modifying benefit in PD, using pioglitazone as a prototypic compound. PPAR-γ is highly expressed in neurons of the substantia nigra and CNS immune cells. Preclinical data in rodent and primate support an effect of TZDs in preventing and/or arresting neurodegeneration and development of motor symptoms. Although no data on the neuroprotective effect of TZDs is currently available, a clinical trial is ongoing where the primary objective is to assess pioglitazone’s impact on the progression of PD. The trial is also evaluating the drug’s safety concerns.
Expert opinion: The efficacy data from clinical trials must be carefully weighed against the safety concerns. However, given the solid preclinical data, and since the safety data are not yet fully conclusive and limited to the diabetic population, PPAR-γ research in PD can continue with caution. Ideally, drug discovery and development efforts will lead to the identification of new compounds with reduced risk of peripheral side effects. 相似文献
目的:研究丙种球蛋白联合甲泼尼松龙治疗小儿吉兰-巴雷综合征(GBS )呼吸肌麻痹的临床疗效,企为临床治疗此病提供更有效的方法。方法:从在我院进行治疗的小儿GBS呼吸肌麻痹患者中,选取64例患者,并签订知情协议书。按照是否具有使用丙种球蛋白治疗的经济能力将患者分为实验组和对照组。实验组使用丙种球蛋白联合甲泼尼松龙治疗,对照组单纯使用甲泼尼松龙治疗,分别观察两组患者的休斯(H ug hes )评分、疗效和不良反应。结果:试验组患者治疗的有效率为94%,显著高于对照组的69%( P=0.010);在患者接受治疗后15 d ,试验组患者的 H ug hes评分是(2.69±1.23)分,明显低于对照组患者(3.34±0.85)分(P=0.017),且在患者接受治疗后6个月时,实验组患者的H ug hes评分是(1.29±0.94)分,亦明显低于对照组患者的(1.87±0.76)分( P=0.028);实验组不良反应的发生率为16%,而对照组不良反应的发生率为22%( P=0.522),差异不具有统计学意义。结论:与单纯使用甲泼尼松龙治疗小儿GBS呼吸肌麻痹相比,使用丙种球蛋白联合甲泼尼松龙治疗的疗效更为显著,且安全性较高,有利于患者病情的早期康复。 相似文献